{"organizations": [], "uuid": "9cebc9ac6be93f430321aa9574e1485425eb214d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180523.html", "section_title": "Archive News &amp; Video for Wednesday, 23 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fda-grants-breakthrough-therapy-de/brief-fda-grants-breakthrough-therapy-designation-to-lenti-d-for-the-treatment-of-cerebral-adrenoleukodystrophy-idUSASC0A3D5", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Grants Breakthrough Therapy Designation To Lenti-D For The Treatment Of Cerebral Adrenoleukodystrophy", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.996, "site_type": "news", "published": "2018-05-23T21:02:00.000+03:00", "replies_count": 0, "uuid": "9cebc9ac6be93f430321aa9574e1485425eb214d"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fda-grants-breakthrough-therapy-de/brief-fda-grants-breakthrough-therapy-designation-to-lenti-d-for-the-treatment-of-cerebral-adrenoleukodystrophy-idUSASC0A3D5", "ord_in_thread": 0, "title": "BRIEF-FDA Grants Breakthrough Therapy Designation To Lenti-D For The Treatment Of Cerebral Adrenoleukodystrophy", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "treatment of cerebral adrenoleukodystrophy", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 23 (Reuters) - bluebird bio Inc:\n* FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO LENTI-Dâ„¢ FOR THE TREATMENT OF CEREBRAL ADRENOLEUKODYSTROPHY\n* BLUEBIRD BIO INC - BREAKTHROUGH THERAPY DESIGNATION IS SUPPORTED BY PRELIMINARY DATA FROM ONGOING PHASE 2/3 STARBEAM STUDY (ALD-102) Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-23T21:02:00.000+03:00", "crawled": "2018-05-24T20:36:54.000+03:00", "highlightTitle": ""}